Novo Integrated Sciences, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert Mattacchione
- Full Time Employees
- 115
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- 11120 NE 2nd Street Bellevue WA United States of America 98004
- IPO Date
- Feb 23, 2021
- CIK
- 0001138978
- Website
- novointegrated.com
- Similar Companies
- Business
- Novo Integrated Sciences, Inc. operates as a multidisciplinary primary care healthcare provider and medical technology company primarily in Canada and the United States. Founded in 1999 and headquartered in Bellevue, Washington, the company offers a comprehensive range of healthcare services including physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy, acupuncture, functional dry needling, chiropody, neurological rehabilitation, kinesiology, vestibular therapy, concussion management, sports medicine therapy, dietitian and holistic nutrition services, fall prevention education, and sports team conditioning programs. Additionally, Novo provides medical technologies such as telemedicine and remote patient monitoring and manufactures wellness products under brands like Terragenx, a micro-dosing iodine product, and ProDip, dietary supplement pouches. The company operates two main segments: healthcare services and product sales. Recent major changes include the acquisition of Acenzia Inc., a nutraceutical health solutions company involved in advanced bio-science R&D, manufacturing, and personalized diagnostics, which strengthens Novo’s decentralized healthcare business model by enhancing its product development and manufacturing capabilities. Novo also completed the acquisition of Clinical Consultants International LLC, further expanding its healthcare services footprint. Financially, Novo secured significant non-dilutive funding arrangements including a $78 million Standby Letter of Credit from HSBC, supporting the acquisition of the Ophir Collection for sole ownership and enabling an increased stock repurchase program. Additionally, Novo’s subsidiary Acenzia was recently selected for a $5.4 million project by Protein Industries Canada to develop plant-based protein products targeting medical nutrition and active living markets, reflecting the company’s strategic focus on innovation and diversified product offerings. Novo’s business model emphasizes three pillars: service networks, technology, and products, aiming to transform non-critical healthcare delivery through integrated care solutions and personalized wellness products. The company maintains a network of clinics primarily across Ontario, Canada, and continues to invest in proprietary medical technologies and therapeutics to enhance patient care and operational efficiency. Novo also pursues strategic partnerships, funding initiatives, and innovations to support sustainable growth and market expansion. Overall, Novo Integrated Sciences combines healthcare service delivery, medical technology innovation, and wellness product manufacturing, targeting a broad spectrum of patients, from pediatric to geriatric populations, with a focus on decentralized, patient-first care models and integrated health solutions in North America.
Novo Integrated Sciences Reports 2024 Fiscal Year Financial Results
Novo Integrated Sciences Reports Fiscal Year 2024 Third Quarter Financial Results
What's Going On With Novo Integrated Sciences Stock On Friday?
Novo Integrated Sciences Receives Commencement of Disbursement Notice for SBLC Leasing and Monetizing Program
Novo Integrated Sciences: A Coil Spring Ready To Explode
Novo Integrated Sciences Receives Confirmation of Issuance of SBLC by HSBC for SBLC Leasing and Monetizing Program
Novo Integrated Sciences' Board of Directors Approves Increase of Maximum Amount Under Stock Repurchase Program to $10 Million
Acenzia Selected to Participate in Protein Industries Canada Program to Develop Plant Based Protein Products
Novo Integrated Sciences and RC Consulting Consortium Group Amend $70,000,000 Promissory Note
KBRA Assigns AA- to Pennsylvania Turnpike Commission Turnpike Revenue Bonds, Series C of 2024; Affirms Related Ratings
Why Is Novo Integrated Sciences (NVOS) Stock Up 139% Today?
Novo Integrated Sciences' Board of Directors Conducting Strategic Review to Increase Maximum Amount under Stock Repurchase Program
Novo Integrated Sciences Receives Confirmation of Ready, Willing and Able (RWA) Issued by HSBC for SBLC Leasing and Monetizing Program
Novo Integrated Sciences Reports Fiscal Year 2024 Second Quarter Financial Results
Novo Integrated Sciences Closes on $6,210,000 Securities Purchase Agreement
Novo Integrated Sciences Provides Update on Certain Current Actions and Events
Novo Integrated Sciences Receives Limited Waiver to Securities Purchase Agreement for $70,000,000 Promissory Note
Novo Integrated Sciences Appoints New President
Novo Integrated Sciences Reports Fiscal Year 2024 First Quarter Financial Results
Blacksheep Trust Files Partial Assignment of $1 Billion Dollar Gold Backed Bond to Novo Integrated Sciences